{"metadata": {"organization_names": [], "person_names_verified": ["michael n. chang", "pedro lichtinger"], "topics": [], "vars": {}, "terms": ["**Exhibit A**", "\u2019s Severance Benefit Plan (the \u201cSeverance Plan\u201d", "\u201cAdditional Term\u201d", "\u201cBoard\u201d", "\u201cCompany\u201d", "\u201cEquity Incentive Plan\u201d", "\u201cInitial Option\u201d", "\u201cInitial Term\u201d", "\u201cRSUs\u201d", "\u201cStart Date\u201d"], "person_names": [], "organization_names_verified": ["optimer pharmaceuticals, inc."], "agreement_id": "276903d65c66d1b314244f97c578b9ac1110a2e7abb5f9a776a02a160d6bdcb4"}}